Arena Capital Advisors’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Arena Capital Advisors’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,251	Closed	-$5.74K	–	146
2022 Q4	$5.74K	Hold	19,251	–	–	﹤0.01%	107
2022 Q3	$1K	Sell	19,251 -50,000	-72%	-$5.46K	﹤0.01%	234
2022 Q2	$7K	Hold	69,251	–	–	﹤0.01%	239
2022 Q1	$14K	Sell	69,251 -31,048	-31%	-$14.5K	﹤0.01%	274
2021 Q4	$60K	Hold	100,299	–	–	0.01%	298
2021 Q3	$62K	Buy	100,299 +75,299	+301%	+$58.6K	﹤0.01%	322
2021 Q2	$24K	Buy	+25,000	New	+$23.3K	﹤0.01%	373

Arena Capital Advisors's EBACW Position: Q1 2023 in Review

Arena Capital Advisors sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 19,251 shares — an estimated $5.74K sold.

Arena Capital Advisors first reported a position in EBACW in Q2 2021 and held it in 7 quarters. The position peaked at $62K in Q3 2021. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

Arena Capital Advisors reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
Arena Capital Advisors sold 19,251 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $5.74K.
Arena Capital Advisors first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 7 quarters.
Arena Capital Advisors's European Biotech Acquisition Corp. Warrant position peaked at $62K in Q3 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Arena Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.